trending Market Intelligence /marketintelligence/en/news-insights/trending/AbrHaoAp3_0vxiuE1GMB2Q2 content esgSubNav
In This List

Hancock Jaffe completes $2.7M common stock placement

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Hancock Jaffe completes $2.7M common stock placement

Hancock Jaffe Laboratories Inc. completed its private placement of 2,360,051 common shares to investors for gross proceeds of about $2.7 million.

The Irvine, Calif.-based medical device company plans to use the proceeds to develop its two lead products, VenoValve and CoreoGraft, and to fund working capital and general corporate purposes.

VenoValve is used for treating chronic venous insufficiency — a debilitating condition under which veins in a patient's legs are not working effectively. CoreoGraft is used during heart surgeries.